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Abstract: Nebivolol is a third generation beta-blocker, which can be distinguished from other 
beta-blockers by its hemodynamic proﬁ  le. It combines beta-adrenergic blocking activity with 
a vasodilating effect mediated by the endothelial L-arginine nitric oxide (NO) pathway. The 
effects of nebivolol have been compared with other beta-blockers and also with other classes 
of antihypertensive agents. In general, response rates to treatment are higher, and the frequency 
and severity of adverse events are either comparable or lower with nebivolol. Nebivolol is 
also effective in reducing cardiovascular morbidity and mortality in elderly patients with heart 
failure, regardless of the initial ejection fraction. Endothelium-derived NO is important in the 
regulation of large arterial stiffness, which in turn is a major risk factor for cardiovascular dis-
ease. Treatment with nebivolol increases the release of NO from the endothelium and improves 
endothelial function, leading to a reduction in arterial stiffness. Decreased arterial stiffness has 
beneﬁ  cial hemodynamic effects including reductions in central aortic blood pressure. Unlike 
ﬁ  rst generation beta-blockerrs, vasodilator beta-blockerrs such as nebivolol have favorable 
hemodynamic effects, which may translate into improved cardiovascular outcomes in patients 
with hypertension.
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Introduction
Hypertension is a major risk factor for cardiovascular disease, and aggressive reduc-
tion of blood pressure can signiﬁ  cantly improve cardiovascular outcomes (Staessen 
et al 2003). However, there is still debate as to whether it is blood pressure reduction 
per se or the antihypertensive agent used that is most important in terms of improving 
cardiovascular outcome. The latest guidelines issued by the National Institute for Clini-
cal Excellence (NICE) for England and Wales recommend an angiotensin-converting 
enzyme inhibitor (or an angiotensin receptor blocker if an ACE inhibitor is not toler-
ated) as ﬁ  rst-line treatment for hypertension in patients less than 55 years old (NICE 
2006). In patients over 55 years and in black patients of any age, the recommended 
ﬁ  rst-line therapy is either a calcium channel blocker or a thiazide-type diuretic.
The NICE guidelines no longer recommend beta-blockers for the ﬁ  rst or second 
line treatment of hypertension. This recommendation was prompted by two recent 
meta-analyses which showed that despite reducing blood pressure, beta blockade was 
not effective in reducing cardiovascular events when compared with either placebo or 
other antihypertensive agents (Carlberg et al 2004; Lindholm et al 2005). Beta-blockers 
have also recently been shown to increase the risk of type 2 diabetes, especially if 
treatment is in combination with a thiazide-type diuretic. However, atenolol was the 
beta-blocker used in most of these studies and, given the relative lack of clinical out-
come data from trials of treating hypertension with beta-blockers other than atenolol, 
it is unclear whether this conclusion applies to all beta-blockers.Vascular Health and Risk Management 2007:3(6) 910
Cockcroft
Isolated systolic hypertension is associated with increased 
large artery stiffness, a strong independent predictor of 
cardiovascular risk. Recently endothelium-derived nitric 
oxide (NO) has been shown to be involved in the regulation 
of large arterial stiffness, with a reduced bioavailability of 
NO production linked to increased arterial stiffness (Kinlay 
et al 2001; Wilkinson et al 2002; Schmitt et al 2005). Arterial 
stiffening associated with age and disease has therefore 
become a new and important therapeutic target in terms of 
blood pressure reduction and cardiovascular disease preven-
tion. Drugs such as nebivolol that reduce blood pressure and 
improve endothelial function may be especially useful in 
this regard and should be considered as an alternative ﬁ  rst-
line treatment for hypertension and in elderly patients with 
chronic heart failure.
Nebivolol
Nebivolol is a third generation beta-blocker, which can be 
distinguished from other beta-blockers by its hemodynamic 
proﬁ  le. The hemodynamic effects of nebivolol are due to 
its vasodilator properties including a reduction in systemic 
vascular resistance and an increase in cardiac output (Ritter 
2001). It is the most beta-1-selective adrenoceptor antagonist 
currently in clinical use and has no alpha-1-blocking action 
(Van Bortel et al 1997). The enantiomers have different 
pharmacological properties. The d-isomer provides the beta-
blocking component (Van Nueten and De Cree 1998) and 
both the d- and l-isomers have an endothelial NO-dependent 
vasodilating effect. Thus racemic nebivolol is needed for 
the drug to be most effective. Such characteristics are in 
contrast to those of carvedilol which also has vasodilatory 
and anti-inﬂ  ammatory properties, but in this case due to its 
ability to block alpha1 receptors. The effects of carvedilol 
on NO bioactivity also remain unclear.
Nebivolol is rapidly absorbed after oral administration of 
a standard 5-mg dose and reaches peak plasma levels between 
30 minutes to 2 hours after intake. It is extensively metabolized 
and excretion is mainly in the feces and urine. The pharma-
cokinetics of nebivolol are not affected by age. However, 
the recommended starting dose for patients over 65 years is 
2.5 mg a day. This is in line with many other antihypertensive 
treatments where dosage is lowered for elderly patients.
Nebivolol (5 mg) is indicated for the treatment of essen-
tial hypertension and, in elderly patients 70 years, for the 
treatment of stable mild and moderate chronic heart failure 
in addition to standard therapies. A starting dose of 2.5 mg 
is suggested in patients over 65 years or in patients with 
renal insufﬁ  ciency.
Nebivolol combines beta-adrenergic blocking activity 
with a vasodilating effect via increased NO availability, 
mediated by the endothelial L-arginine NO pathway, 
leading to a reduction in peripheral vascular resistance. 
Treatment with nebivolol also leads to improvements in 
left ventricular function in patients with heart failure (Uhlir 
et al 1991; Erdogan et al 2007; Lombardo et al 2006), and 
arterial compliance (Van Merode et al 1989). Left ventricular 
function is preserved and left ventricular mass is reduced 
in hypertensive patients with left ventricular hypertrophy 
(Stoleru et al 1993).
Hypertensive patients are at high risk of coronary artery 
disease and subsequent impaired cardiac function (Robertson 
and Ball 1994) and congestive heart failure. Endothelial dys-
function, characterized by decreased bioavailability of NO, 
also occurs early in various forms of cardiovascular disease. 
NO has powerful antiatherogenic effects and a decrease in 
NO production is associated with a number of cardiovas-
cular risk factors including hypertension, diabetes mellitus 
and hypercholesterolemia. Endothelial dysfunction may 
therefore contribute to the pathogenesis of atherosclerosis 
in hypertension (Moncada 1994). Treatment with nebivolol 
may thus favorably impact on the vascular complications of 
hypertension either directly by reducing blood pressure or 
indirectly by increasing the bioavailability of NO. In healthy 
volunteers, nebivolol (5 mg) decreases systemic vascular 
resistance with no impairment of left ventricular function 
(Van de Water et al 1988). In addition, chronic treatment 
with nebivolol maintains left ventricular function in healthy 
volunteers and in patients with hypertension (De Cree et al 
1991), acute myocardial infarction and congestive heart 
failure (Stoleru et al 1993).
Central aortic pressure is a strong predictor of cardiovas-
cular morbidity and mortality but classic beta-blockers such 
as atenolol have little effect on reducing central aortic pulse 
pressure in hypertensive patients. Studies comparing atenolol 
with other antihypertensive agents show that although 
decreases in peripheral blood pressure are similar, treatment 
with atenolol results in signiﬁ  cantly less reduction of central 
aortic pressure compared with either fosinopril (Chen et al 
1995) or eprosartan (Dhakam et al 2006). Improvements in 
arterial stiffness and arterial compliance are also greater with 
calcium channel blockers, angiotensin-converting enzyme 
inhibitors, and angiotensin II receptor blockers compared 
with atenolol (Resnick and Lester 2002).
The lack of efﬁ  cacy of atenolol in reducing central pres-
sure can have a direct effect on cardiovascular outcomes. In 
the CAFE study (Williams et al 2006) both brachial and aortic Vascular Health and Risk Management 2007:3(6) 911
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pressures were measured using pulse wave analysis in 2199 
patients originally enrolled for the ASCOT trial. Patients 
treated with amlodipine/perindopril had greater reductions 
in central aortic systolic pressure and central aortic pulse 
pressure compared with patients given atenolol/bendroﬂ  ua-
zide, even though reductions in brachial blood pressure were 
similar across the treatment groups. In addition, central aortic 
pulse pressure was an independent determinant of cardiovas-
cular outcomes and may help to explain why, in the ASCOT 
trial, clinical outcomes were worse in patients treated with 
atenolol/bendroﬂ  uazide.
Atenolol may be less effective at reducing central aortic 
pressure because of its effects on reducing heart rate which 
may enhance the effect of wave reﬂ  ections (Wilkinson et al 
2006). The additional vasodilatory effects of nebivolol con-
tribute to a lower reduction in heart rate, and the subsequent 
decrease in wave reﬂ  ection together with improvements in 
arterial stiffness, and endothelial dysfunction may offset 
such deleterious hemodynamic effects and thus lower central 
pressure more than atenolol. This may translate clinically into 
greater reductions in cardiovascular morbidity and mortality 
than those seen with traditional beta-blockers (Kelly et al 
1989; Pedersen and Cockcroft 2006), although this remains 
as yet unproven.
Clinical efﬁ  cacy of nebivolol
in hypertension
The efﬁ  cacy of nebivolol monotherapy has been extensively 
studied in patients with mild to moderate hypertension. Early 
double-blind, placebo-controlled studies showed signiﬁ  cant 
reductions of blood pressure with a daily dose of 5 mg 
nebivolol (Van Bortel and Van Baak 1992; Van Nueten et al 
1997a). Nebivolol was equally effective in black patients, 
with a notable absence of typical side-effects usually associ-
ated with beta-blockade. Nebivolol did not impair Quality of 
life, measured with the Inventory of Subjective Health (ISH), 
and the frequency of adverse events was similar between 
nebivolol and placebo (Van Bortel et al 1993).
A recent follow-up study was conducted in order to 
establish whether the reported efﬁ  cacy and safety of nebivolol 
can be generalized in a large nationwide study (Cleophas 
et al 2006). A total of 6356 patients with mild hypertension 
were treated with nebivolol for 6 weeks. No serious adverse 
events occurred during the study, and the occurrence of minor 
adverse events was very limited. Blood pressure was signiﬁ  -
cantly reduced and the efﬁ  cacy of nebivolol monotherapy 
and add-on therapy was similar. Nebivolol was also highly 
effective in patients with isolated systolic hypertension.
Cleophas et al (2001) have assessed the long-term efﬁ  cacy 
of nebivolol monotherapy. The study found a greater reduc-
tion in blood pressure and a higher percentage of responders 
after 6 months of nebivolol treatment. Nebivolol was well 
tolerated and patients reported a better feeling of general 
well being compared with any previous monotherapies. 
Although current guidelines recommend the adjustment of 
antihypertensive drug therapy after 6–8 weeks of treatment 
(WHO-ISH 1999), such a strategy may not be appropriate 
for optimal nebivolol treatment.
In a 6-week observational study, nebivolol reduced both 
systolic and diastolic blood pressures and, unlike ﬁ  rst gen-
eration beta-blockerrs, there were signiﬁ  cant reductions 
in cholesterol, triglycerides, and blood sugar (Fallois and 
Faulhaber 2001). Results of studies comparing the efﬁ  cacy 
and safety of nebivolol compared with other beta-blockers 
and other classes of antihypertensive agents generally ﬁ  nd 
response rates to treatment are higher, and the frequency and 
severity of adverse events are either comparable or lower 
with nebivolol.
Nebivolol vs other beta-blockers
The antihypertensive effects of nebivolol are similar to those 
of the classic beta-blockers but the unique hemodynamic 
proﬁ  le of nebivolol may contribute to its additional reported 
beneﬁ  ts. For example, in a double blind, randomized study 
in patients with untreated essential hypertension (Kamp et al 
2003), both nebivolol (5 mg/day) and atenolol (100 mg/day) 
signiﬁ  cantly reduced blood pressure to a similar extent. 
However, nebivolol also signiﬁ  cantly reduced heart rate and 
peripheral resistance and increased stroke volume, leading to 
a small increase in cardiac output whereas cardiac output was 
signiﬁ  cantly decreased and peripheral resistance increased 
with atenolol. The improvements in diastolic function with 
nebivolol highlight its potential use in the treatment of heart 
failure.
A separate double blind, randomized, parallel group 
trial compared patients treated for 4 weeks with nebivolol 
(5 mg/day), atenolol (50 mg/day), or placebo. Both nebivolol 
and atenolol signiﬁ  cantly reduced blood pressure compared 
with placebo while nebivolol had no orthostatic effects 
and was better tolerated than atenolol (Van Nueten et al 
1998b). Similar results were found when nebivolol was 
compared with metoprolol (Uhlir et al 1991).
The unique hemodynamic proﬁ  le of nebivolol may also 
contribute to the maintenance of exercise capacity compared 
with other beta-blockers. In a double blind, placebo-
controlled, cross-over study of exercise tolerance in healthy Vascular Health and Risk Management 2007:3(6) 912
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volunteers given nebivolol (5 mg) or atenolol (100 mg) for 
2 weeks, exercise capacity was lower and fatigue higher with 
atenolol compared with nebivolol (Van Bortel and Van Baak 
1992). Nebivolol also signiﬁ  cantly decreased the total periph-
eral resistance during exercise compared with placebo.
Nebivolol vs other classes
of antihypertensive agents
Nebivolol is an effective antihypertensive agent with a supe-
rior tolerability proﬁ  le in comparison with other classes of 
antihypertensive agents. In a double-blind study comparing 
hypertensive patients treated with nebivolol (5 mg) or the 
angiotensin-converting enzyme inhibitor enalapril (10 mg) 
for 3 months, the decrease in blood pressure was signiﬁ  -
cantly higher and response rates were higher with nebivolol 
(Van Nueten et al 1997b). The incidence of cough was also 
higher with enalapril.
Although nebivolol (5 mg) and the calcium antagonist 
nifedipine (20 mg) were equally effective in lowering blood 
pressure, nebivolol also signiﬁ  cantly reduced heart rate 
(Van Nueten et al 1998a) and adverse events associated with 
nifedipine treatment caused a signiﬁ  cantly higher number of 
patients to withdraw from the study compared with nebivo-
lol-treated patients. Heart rate was also signiﬁ  cantly reduced 
with nebivolol in a study comparing nebivolol (2.5–5 mg) 
with the calcium channel blocker amlodipine (5–10 mg) in 
elderly patients with mild to moderate hypertension (Mazza 
et al 2002). A high heart rate is linked to an increased risk 
of death in the elderly (Palatini et al 1999) and so an anti-
hypertensive such as nebivolol that effectively lowers blood 
pressure and also lowers heart rate has dual beneﬁ  ts in this 
population.
Effects of nebivolol and the angiotensin receptor blocker 
losartan on quality of life and antihypertensive effects were 
compared in a double-blind, randomized, parallel group 
study (Van Bortel et al 2005). Patients with hypertension 
were treated for 12 weeks with 5 mg of nebivolol or 50 mg 
of losartan once daily. Quality of life parameters did not 
differ between the two treatments and although both drugs 
decreased systolic blood pressure similarly, the decrease 
in diastolic blood pressure was signiﬁ  cantly greater with 
nebivolol.
Type 2 diabetes
Endothelial dysfunction, leading to decreased bioavailability 
of NO, is one of the major underlying mechanisms linking 
cardiovascular risk factors such as hypertension, diabetes 
mellitus, and dyslipidemia to overt cardiovascular disease 
(Mason 2006). In addition, tight control of blood pressure 
is more effective at reducing cardiovascular events than 
tight control of blood sugar in diabetic patients (Palatini 
et al 1999). Unlike some beta-blockerrs, nebivolol had no 
effect on insulin sensitivity and glucose tolerance (Fogari 
et al 1997) and may therefore have potential therapeutic 
beneﬁ  ts in patients with type 2 diabetes, especially as many 
diabetic patients develop hypertension during the course of 
their disease (Kannel et al 1991).
Arterial stiffness and cardiovascular 
risk
Arterial stiffness is a consequence of age (Kass 2002) and 
also of conditions such as diabetes and hypercholesterolemia, 
which cause premature vascular aging. Arterial stiffness 
is a major risk factor for cardiovascular disease and is an 
important predictor of mortality in hypertensive patients 
(Laurent et al 2001). Increased aortic stiffness is also an 
independent predictor of diastolic dysfunction in patients 
with hypertensive heart disease (Yambe et al 2004; Mottram 
et al 2005) (see also Figure 1), and may also limit exercise 
tolerance in patients with dilated cardiomyopathy (Bonapace 
et al 2003). Patients who have heart failure with a preserved 
ejection fraction present with ventricular-systolic and arterial 
stiffening beyond that expected with age and/or hypertension 
(Kawaguchi et al 2003). Ventricular-vascular stiffening may 
also be greater in elderly women compared with elderly men 
(Redﬁ  eld et al 2005). Therefore, therapies aimed at reducing 
arterial stiffening may be of use in the treatment of diastolic 
dysfunction and heart failure.
Aortic pulse wave velocity (PWV) is a direct measure of 
arterial stiffness and may be a better predictor of future cardio-
vascular events compared with established risk factors such as 
age, hypertension, hypercholesterolemia, and diabetes. Stud-
ies using PWV ﬁ  nd that increased arterial stiffness can predict 
cardiovascular risk in apparently healthy subjects (van Popele 
et al 2006), patients with hypertension (Boutouyrie et al 
2002), diabetes (Cruickshank et al 2002), end-stage renal 
failure (Blacher et al 1999), and older individuals (Meaume 
et al 2001). Arterial stiffness is also a possible risk factor for 
diastolic heart failure in hypertensive patients.
Pulse pressure, determined by large artery compliance and 
the pattern of left ventricular ejection, is a surrogate mea-
sure of arterial stiffness. In older patients, pulse pressure is 
a more important determinant of cardiovascular prognosis 
than mean arterial pressure in normotensive (Benetos et al 
1997), hypertensive (Benetos et al 1998) and post-myocardial 
infarction populations (Mitchell et al 1997). These ﬁ  ndings Vascular Health and Risk Management 2007:3(6) 913
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are conﬁ  rmed by recent re-analysis (Millar et al 1999) and 
meta-analysis (Blacher et al 2000) of blood pressure lower-
ing studies. Patients with congestive heart failure have an 
elevated central pulsatile load, which may help to explain 
why an increased pulse pressure is linked to an increase in 
clinical events in such patients (Mitchell et al 2001). Thera-
pies that help to reduce such abnormal loading of the heart 
may be of use in the treatment of congestive heart failure.
An increased PWV and amplitude of the pressure wave 
reﬂ  ected back to the aorta can cause increases in central aortic 
pressure, leading to increased left ventricular workload. Cen-
tral aortic pressure is therefore an independent predictor of 
cardiovascular morbidity and mortality. Indeed, patients with 
high aortic pressure have a worse cardiovascular prognosis 
than patients with more effective control of central aortic 
pressure (Williams et al 2006).
Increased arterial stiffness is linked to endothelial dys-
function and reduced bioavailability of NO (Wilkinson et al 
2004). Endothelial dysfunction, which is found in patients 
with most cardiovascular risk factors, may explain why these 
conditions are also associated with increased arterial stiff-
ness at an early stage before the development of manifest 
atheroma (Cockcroft et al 1997). Therefore, drugs such as 
nebivolol that can increase NO production may help to reduce 
large artery stiffness which in turn may lead to a reduction 
of cardiovascular risk.
Antihypertensive agents differ in their effects on large 
arterial stiffness and pulse wave reﬂ  ection (Chen et al 1995; 
Van Bortel et al 1995; Breithaupt-Grogler et al 1996; Dreary 
et al 2002). However, some of the beneﬁ  cial effects observed 
may simply be due to the passive effect of lowering mean 
arterial pressure. The classical ﬁ  rst generation beta-blockers 
such as atenolol have been shown to actually increase pulse 
wave reﬂ  ection and central pressure acutely (O’Rourke et al 
1989). Nebivolol decreases arterial stiffness independently of 
any effect on blood pressure (McEniery et al 2004). Such vaso-
dilating effects of nebivolol may help to reduce cardiovascular 
risk and improve outcomes, although such beneﬁ  ts need to be 
conﬁ  rmed by the data from longer-term intervention trials.
Clinical efﬁ  cacy of nebivolol
in chronic heart failure
A large, randomized, double-blind, placebo-controlled study 
(SENIORS study), has assessed the effects of nebivolol 
on mortality and morbidity in elderly patients 70 years 
with a history of heart failure (Flather et al 2005). Patients 
were started on a dose of 1.25 mg nebivolol once daily and 
titrated to a target dose of 10 mg over a mean of seven weeks. 
DIASTOLIC DYSFUNCTION
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Coronary perfusion
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LV afterload
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AORTIC STIFFENING
Figure 1 Pathophysiological pathways through which aortic stiffness may contribute to the development of diastolic dysfunction. DBP, diastolic blood pressure; SBP, systolic 
blood pressure. Reproduced with permission from Mottram PM, Haluska BA, Leano R et al 2005. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart 
disease. Heart, 91:1551–6. Copyright © 2005. BMJ Publishing Group Ltd.Vascular Health and Risk Management 2007:3(6) 914
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Although nebivolol did not signiﬁ  cantly reduce mortality, 
the composite risk of all cause mortality or cardiovascular 
hospital admission (time to ﬁ  rst event) was signiﬁ  cantly 
reduced by 15% with nebivolol compared with placebo 
(Figure 2). This risk reduction was lower than that seen in 
previous trials with other beta-blockers (Shibata et al 2001). 
However, a sub-analysis of data from patients most similar 
to patients of these earlier trials showed the risk reduction 
to increase to 27%. Such results indicate that nebivolol has 
comparable beneﬁ  ts to those of other beta-blockers studied 
in heart failure. The beneﬁ  ts of treatment appeared after 
6 months and the risk reduction increased if treatment was 
continued. The beneﬁ  ts of beta-blockade were independent of 
the initial ejection fraction and were observed even in patients 
with mild left ventricular dysfunction or preserved ventricular 
function. The vasodilating effects speciﬁ  c to nebivolol may 
help to improve tolerability in elderly patients with heart 
failure and support the use of this particular beta-blocker to 
treat heart failure in an elderly population.
Safety and tolerability
Nebivolol is well-tolerated in patients with hypertension. In 
clinical trials, reported adverse events are mostly mild to mod-
erate in nature with an incidence similar to that observed with 
placebo (Tzemos et al 2001). Meta-analysis of the incidence 
of adverse events in double-blind, placebo-controlled trials 
ﬁ  nds the occurrence of adverse events to be no different with 
nebivolol compared with placebo (Lacourciere and Arnott 
1994; Van Nueten et al 1998a) and doses of up to 30 mg 
(6 times the recommended dose) have been well tolerated. 
Adverse events typical of classical beta-blockers are lower 
with nebivolol (Steiner et al 1990). Classical beta-blockers 
may also alter plasma lipids in a potentially adverse manner 
(Cruickshank and Prichard 1987) whereas patients treated for 
3 months with up to 10 mg daily nebivolol show no changes 
in plasma total cholesterol, triglycerides, lipoproteins, and 
apolipoproteins (Lacourciere et al 1992; Van Nueten et al 
1997b; Tzemos et al 2001). Quality of life, assessed using the 
Inventory of Subjective Health, is not impaired with nebivolol 
treatment (Van Bortel et al 1993) and in general is similar to 
that reported with both atenolol and losartan (Van Nueten 
et al 1998c; Van Bortel et al 2005).
In the SENIORS study in elderly patients with chronic 
heart failure, the tolerability of nebivolol was similar to 
placebo (Flather et al 2005). Drug-related adverse events 
were typical of those associated with beta-blockers and 
included hypotension, bradycardia and dizziness.
Endothelial function and the role 
of nitric oxide
The vascular endothelium modulates the tone and structure 
of the blood vessel smooth muscle by releasing various 
vasoactive and relaxing factors. One of the most important 
appears to be NO, a potent endogenous smooth muscle 
dilator, synthesized from the amino acid L-arginine, via 
the action of the constitutive enzyme nitric oxide synthase 
(Palmer et al 1988). NO regulates basal vascular tone and 
blood pressure and also has powerful antiatherogenic proper-
ties. Endothelial dysfunction, manifested by reduced arterial 
vasodilation, is linked to abnormalities of the L-arginine/NO 
pathway resulting in decreased bioavailability of NO. Such 
dysfunction can therefore predispose to atherogenesis and 
may represent a link between conditions associated with 
increased cardiovascular risk (including diabetes, hyper-
cholesterolemia and hypertension) and the development 
of overt cardiovascular disease (Moncada 1994; Brunner 
et al 2005).
Nebivolol can improve endothelial function directly via an 
effect on the endothelial L-arginine/NO pathway. Nebivolol 
relaxes precontracted canine coronary artery strips only if the 
endothelium is intact (Stoleru et al 1993) and this vasorelax-
ant effect is antagonized by nitro-L-arginine, an inhibitor 
of NO production, implying that the effect is mediated via 
release of endothelium-derived NO (Gao et al 1991).
Similar ﬁ  ndings have been reported in vivo in a human 
vascular bed (Cockcroft et al 1995). Infusion of nebivolol 
Figure 2 Time to ﬁ  rst occurrence of events (all cause death or hospital admission 
for a cardiovascular reason – primary endpoint). Flather MD, Shibata MC, Coats AJ 
et al 2005. Randomized trial to determine the effect of nebivolol on mortality and 
cardiovascular hospital admission in elderly patients with heart failure (SENIORS). 
Eur Heart J, 26:215–25. Copyright © 2005. Oxford University Press.
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into the brachial artery of healthy volunteers resulted in 
vasodilation and an increase in forearm blood ﬂ  ow by an 
average of 90% whereas atenolol had no effect. The vaso-
dilator effect was signiﬁ  cantly reduced with co-infusion of 
L-NMMA and this inhibition was abolished by L-arginine, 
the substrate for NO production, suggesting that the L-argi-
nine/nitric oxide pathway was involved. Similar effects of 
nebivolol have also been demonstrated in experiments of 
nebivolol infusion into superﬁ  cial hand veins (Bowman et al 
1994) and in patients with hypertension (Dawes et al 1999). 
Oral nebivolol, but not atenolol, can also improve both basal 
and stimulated NO release relative to placebo in patients with 
essential hypertension (Tzemos et al 2001).
The improvements in endothelial function, secondary to 
release of NO, seen with nebivolol are of particular impor-
tance in black patients. This patient group has a reduced 
bioavailability of NO and alterations in endothelial function 
which may contribute to the greater susceptibility to cardio-
vascular disease observed in black patients. Pre-treatment 
with nebivolol of endothelial cells from black patients can 
increase NO bioavailability to levels similar to those in endo-
thelial cells from white patients thereby helping to reverse 
endothelial dysfunction (Mason et al 2005).
Conclusion
Nebivolol is a third generation beta-blocker and is an 
effective antihypertensive with a good tolerability pro-
ﬁ  le. Adverse events are generally mild with an incidence 
similar to placebo and there is a low incidence of many of 
the side effects usually associated with the use of classical 
beta-blockers. Nebivolol is also effective in reducing mor-
bidity and mortality in elderly patients with heart failure, 
regardless of the initial ejection fraction. In addition to its 
effectiveness as an antihypertensive, nebivolol has a unique 
hemodynamic proﬁ  le. Treatment with nebivolol increases 
NO bioavailability, improves endothelial function, leading to 
a reduction in arterial stiffness which in turn can help lower 
central aortic pressure. Such effects of nebivolol have the 
potential to reduce cardiovascular events. Additional studies 
are needed to determine the long term clinical relevance of 
these ﬁ  ndings in the treatment of hypertension and cardio-
vascular disease.
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